NGNE: SEC Form 10-K filed by Neurogene Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for NGNE
Across the 11 sessions after earlier NGNE headlines, the stock closed higher 3 times and lower 8 times, with a median move of 8.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NGNE | SPY |
|---|---|---|---|
| Mar 24, 2026 | Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates | +8.0% | -0.3% |
| Mar 11, 2026 | Neurogene to Participate in Stifel 2026 Virtual CNS Forum | -0.2% | -0.1% |
| Mar 4, 2026 | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +8.7% | +0.7% |
| Feb 27, 2026 | Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome | +19.4% | -0.5% |
| Feb 5, 2026 | Neurogene to Participate in Upcoming Investor Conferencesand 1 other headline that session | -4.7% | -1.2% |
| Jan 12, 2026 | Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome | -3.6% | +0.2% |
Quantisnow market dataNASDAQ
NGNE
Neurogene Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Get push alerts for NGNE
Full NGNE profile on Quantisnow Follow NGNE and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time